American CryoStem and Protein Genomics (PGen) have agreed to work together to develop cellular therapies for the wound healing and other regenerative markets. The companies will initially focus their efforts toward creating applications for injuries and conditions that are difficult to treat, such as chronic, acute, and traumatic wounds.
American CryoStem will contribute certain intellectual property, know-how, and trade secrets, including clinically prepared adipose-derived stem cells using the company's tissue processing products and stromal cell culture media. PGen will contribute certain know-how and trade secrets as well as patented Elastatropin® human-based protein.
Elastatropin, or human tropoelastin, is an over-the-counter product for wound closure applications. Tropoelastin is a precursor to elastin, a molecule in the extracellular matrix that, in particular, provides strength and elasticity of skin. PGen’s development and production of human tropoelastin for wound healing has resulted in new discoveries that permit additional uses.
American CryoStem markets clinical processing services and patented products for adipose tissue and adipose-derived adult stem cells. The firm provides clinical processing, patented cell culture media products, and a cellular preservation platform.
“Discussions have been under way for some time, and this formalized collaborative agreement is phase one of combining these two unique patented technologies,” says John Arnone, CEO of American CryoStem. “This collaboration is part of the company's efforts to leverage its clinical laboratory processes into the cellular therapy and regenerative medicine application market.”